1. High-Alert Medication Safety Framework
The Institute for Safe Medication Practices (ISMP) defines high-alert medications as pharmaceuticals bearing a heightened risk of causing significant patient harm when used in error. In parenteral infusion therapy, biological response modifiers, parenteral iron complexes, antineoplastic agents, and intravenous immunoglobulins carry unique pharmacodynamic properties requiring meticulous titration schedules, allergy cross-matching, and independent bedside double-checks.
Safe administration mandates comprehensive understanding of formulation differences, premedication protocols, filter pore requirements, and the clinical distinction between benign infusion reactions and life-threatening anaphylaxis.
2. Clinical Infusion Therapy Practice Guides
IV Iron Therapy Safety
Pharmacokinetics of modern carbohydrate complexes (Injectafer, Venofer, Feraheme), differentiating Fishbane reactions from anaphylaxis, and pre-medication.
IVIG Administration
Stepwise rate titration curves, vigorous pre-hydration, prevention of aseptic meningitis migraines, and sucrose-free formulation safety.
Infliximab (Remicade®) Safety
Monoclonal antibody administration, low-protein-binding 0.22 µm in-line filters, reaction staging, and accelerated maintenance schedules.
Chemotherapy Safety
Independent dual-nurse verification, BSA Mosteller calculations, vesicant administration sequencing, and vascular patency monitoring.
Home IV Antibiotics (OPAT)
Elastomeric balloon pumps, electronic ambulatory cassettes, SASH flushing protocols, and therapeutic vancomycin drug monitoring.